×
About 9,478 results

ALLMedicine™ Plaque Psoriasis Center

Research & Reviews  2,274 results

AVT02: An Adalimumab Biosimilar.
https://doi.org/10.1007/s40261-022-01196-w
Clinical Drug Investigation; Kang C

Oct 2nd, 2022 - AVT02 (Hukyndra®, Libmyris®) is a biosimilar of the reference anti-tumour necrosis factor alpha monoclonal antibody adalimumab. It is approved for use in all indications for which reference adalimumab is approved. AVT02 has similar physicochemical...

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04053881

Sep 30th, 2022 - The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
https://clinicaltrials.gov/ct2/show/NCT04053387

Sep 29th, 2022 - At the completion of the Week-12 visit of the pivotal study (Baseline [Day 1] in this study), all eligible subjects will be offered enrollment in the long-term extension study. Study visits during the treatment period for all subjects will occur e...

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05357755

Sep 28th, 2022 - The population of people living with moderate to severe psoriasis is approximately 3.5 billion who are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin wh...

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03598790

Sep 28th, 2022 - The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.

see more →

Guidelines  2 results

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/
Arcutis Biotherapeutics, Inc.

Jul 29th, 2022 - WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that t...

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

see more →

Drugs  138 results see all →

Clinicaltrials.gov  662 results

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04053881

Sep 30th, 2022 - The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
https://clinicaltrials.gov/ct2/show/NCT04053387

Sep 29th, 2022 - At the completion of the Week-12 visit of the pivotal study (Baseline [Day 1] in this study), all eligible subjects will be offered enrollment in the long-term extension study. Study visits during the treatment period for all subjects will occur e...

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05357755

Sep 28th, 2022 - The population of people living with moderate to severe psoriasis is approximately 3.5 billion who are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin wh...

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03598790

Sep 28th, 2022 - The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05364554

Sep 28th, 2022 - The populations of people living with moderate to severe psoriasis is approximately 3.5 billion which are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin...

see more →

News  714 results

Open Clinical Trials for Psoriasis
https://www.mdedge.com/dermatology/article/258022/psoriasis/open-clinical-trials-psoriasis

Sep 19th, 2022 - The psoriasis clinical trials listed below are all phase 3 and recruiting participants as of July 19, 2022. For additional information on the study design, eligibility criteria, and contacts/locations, visit ClinicalTrials.

Brodalumab suicide risk similar to other biologics, postmarket study finds
https://www.mdedge.com/dermatology/article/258020/psoriasis/brodalumab-suicide-risk-similar-other-biologics-postmarket
Christine Kilgore

Sep 19th, 2022 - An analysis of postmarketing suicide data shows that the risk of suicide associated with brodalumab use is similar to that of other biologics prescribed for psoriasis. The Food and Drug Administration approved brodalumab (Siliq) in 2017 for treatm.

Apremilast Alleviates Severe Psoriasis in Some Children, Data Show
https://www.medscape.com/viewarticle/981012

Sep 19th, 2022 - Apremilast (Otezla), an oral drug approved for adult psoriasis, appears to reduce psoriasis severity in some children with moderate to severe psoriasis not controlled by topical therapy, according to the results of a phase 3 trial. "Unfortunately,...

Brodalumab Suicide Risk Similar to Other Biologics, Postmarketing Study Finds
https://www.medscape.com/viewarticle/981038

Sep 19th, 2022 - An analysis of postmarketing suicide data shows that the risk of suicide associated with brodalumab use is similar to that of other biologics prescribed for psoriasis. The Food and Drug Administration approved brodalumab (Siliq) in 2017 for treatm...

Sustained response at 2 years reported for newly approved oral psoriasis agent
https://www.mdedge.com/dermatology/article/257871/psoriasis/sustained-response-2-years-reported-newly-approved-oral
Ted Bosworth

Sep 15th, 2022 - MILAN – The day after deucravacitinib became the first TYK2 inhibitor approved for the treatment of moderate to severe psoriasis, long-term data were presented at the annual congress of the European Academy of Dermatology and Venereology, suggesti.

see more →

Patient Education  1 results see all →